Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Most Read

  1. Poxel closes enrolment in TIMES 2 trial of Imeglimin in Japan
  2. Cocrystal Pharma to study hepatitis C drug in Hong Kong
  3. Allergan assesses brazikumab in two clinical programmes for IBD
  4. Cardax doses first patient in CHASE trial for cardiovascular health drug
  5. Oxurion enrols first patient in Phase l trial of THR-687 for DME

Latest Content

Roche’s Tecentriq triplet versus Keytruda + chemotherapy: an Uphill Struggle?

On December 7 Roche announced the FDA approval of its triplet of programmed death-ligand 1 (PD-L1) inhibitor Tecentriq (atezolizumab) + vascular endothelial growth factor (VEGF) inhibitor Avastin (bevacizumab) + chemotherapy (paclitaxel + carboplatin) in the highly prized indication of untreated non-squamous non-small cell lung cancer (NSCLC).

Quick and Flexible Elemental Screening with Omnian

Omnian was developed for Malvern Panalytical's high-end x-ray fluorescence (XRD) spectrometer and is also available for the Epsilon 4 energy dispersive x-ray fluorescence (EDXRF) benchtop systems. This powerful combination brings together the strengths of Omnian with the ease-of-use of Epsilon 4.

Janssen reports positive results from plaque psoriasis trial

Janssen Pharmaceutical Companies of Johnson & Johnson has reported positive results from the Phase III ECLIPSE trial that investigated the efficacy and safety of tremfya (guselkumab) in comparison with cosentyx (secukinumab) in adult patients with moderate to severe plaque psoriasis.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top